Kyverna Therapeutics, Inc. KYTX Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

Climb Bio, Inc.CLYM

$305K-54.4%

Artiva Biotherapeutics, Inc.ARTV

$199K-72.5%

Iovance Biotherapeutics, Inc.IOVA

$1.12M-47.8%

Viridian Therapeutics, Inc.VRDN

$1.86M-20.0%

CytomX TherapeuticsCTMX

$726K+59.9%

Janux TherapeuticsJANX

$2.62M-37.8%

Questions, answered.

What is Kyverna Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?

Kyverna Therapeutics, Inc. (KYTX) reported accretion (amortization) of discounts and premiums, investments of $730K in Q1 2026.

How has Kyverna Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?

Kyverna Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 65.4% year-over-year, from $2.11M to $730K.

What is the long-term trend for Kyverna Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?

Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments has grown at a 147.7% compound annual growth rate (CAGR), from $1.12M to $6.89M.

What does accretion (amortization) of discounts and premiums, investments mean?

This represents the non-cash adjustment to interest income or expense resulting from the amortization of premiums or accretion of discounts on investment securities. It reconciles the difference between the purchase price of an investment and its face value over the holding period. This adjustment is essential for accurately reflecting the effective yield of the company's investment portfolio in operating cash flows.